Conjunctival papilloma.
Tseng
Sung-Huei
SH
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D052163:Human papillomavirus 6 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000821:virology; D010212:Papilloma / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D011092:Polyethylene Glycols; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b